- Actuate Therapeutics, Inc.
Actuate Therapeutics, Inc.
Website
Offer Price
Offer Size
3-Year Outlook
Volatility
1st Day Turnover
$8.00
2,800,000
Positive
High
3.28%
Offering Team
Deal Managers
- Titan Partners
Lawyers
- Baker and Hostetler LLP
Auditors
- KMJ Corbin & Company LLP
Pre-IPO Investors
Investors
- Google Ventures
- Intel Ventures
- Patricoff Ventures
- Kleiner Perkins
Pre-IPO Holdings(%)
- 30
- 20
- 05
- 18
Deal Highlights
We are a clinical stage biopharmaceutical company focused on developing therapies for the treatment of high impact, difficult to treat cancers through the inhibition of glycogen synthase kinase-3 (GSK-3). We are developing elraglusib (formerly 9-ING-41), a small molecule that is designed to enter cancer cells and block the function of the enzyme GSK-3, a master regulator of complex biological signaling cascades, including those mediated by oncogenes, that lead to tumor cell s More
Deal Tracker
Investors
Filing
24 May, 2024Offer
13 Aug, 2024Look Ahead
Lock Up Expiry
13 Feb, 2025Earning
Nov 1, 2018IPO Terms
| Offer Price | $8.00 |
| Offer Size | 2M |